Term ends Jun 23, 2033 · High confidence
20-year base term ends Sep 24, 2027
Held by Celgene International II SARL
Filed Sep 24, 2007 as application 11/860,491 · Granted Mar 24, 2015
Base term plus 2099 days of patent term adjustment (USPTO delay)
Today
2007
2033
Clock starts
Sep 24, 2007
Sep 24, 2007
Term ends
Jun 23, 2033
Jun 23, 2033
Granted
Mar 24, 2015
Mar 24, 2015
base term
patent term adjustment
fee events
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
2,099
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
4
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 2099 days past its 20-year base term on prosecution delay. 2 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Sep 24, 2007, when this application, 11/860,491, was filed | Sep 24, 2027 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +2099 days, USPTO patent term adjustment record | Jun 23, 2033 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jun 23, 2033 | High confidence |
This family
| US 8,986,971 | this patent Jun 2033 | Jun 2033 |
| US 10,011,814 | Lapsed on the fee record Jul 2026 | Jul 2026 |
| US 10,793,824 | In force Nov 2027 | Nov 2027 |
| Application 17/006,334 | Abandoned not computed | not computed |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Feb 19, 2008 Reel 20529, frame 853 | Lam, Kin Sing; Tsueng, Ginger | Nereus Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| May 21, 2009 Reel 22719, frame 115 | Nereus Pharmaceuticals, Inc. | HBM Bioventures (Cayman) Ltd.; HBM Biocapital (Eur) L.P.; HBM Biocapital (Usd) L.P.; Private Life Biomed AG; Alstertor Private Life GmbH & Co. KG; Advent Healthcare and Life Sciences III Limited Partnership; Advent Healthcare and Life Sciences III-A Limited Partnership; Advent Partners HLS III Limited Partnership; Pacific Venture Group II, L.P.; Pvg Associates Ii, L.p.; Forward Ventures Iv, L.p.; Forward Ventures IV B, L.P.; Gimv N.V.; Gimv Adviesbeheer Life Sciences N.V.; Lotus Bioscience Investment Holds Ltd.; Novartis Bioventure Fund / Novartis International Aig; Hensler, Mary; Jacobs, Robert; WS Investment Company; Genavent Partners LP; Astellas Venture Fund I LP; Roche Finance Ltd.; Alta California Partners II, L.P.; Alta Embarcadero Partners II, LLC; Alta California Partners II, L.P. - New Pool | Security Agreement |
| May 21, 2009 reel/frame not recorded | Nereus Pharmaceuticals, Inc. | HBM Bioventures (Cayman) Ltd. | Security Agreement |
| May 21, 2009 reel/frame not recorded | Nereus Pharmaceuticals, Inc. | HBM Biocapital (Eur) L.P. | Security Agreement |
| May 21, 2009 reel/frame not recorded | Nereus Pharmaceuticals, Inc. | HBM Biocapital (Usd) L.P. | Security Agreement |
| May 21, 2009 reel/frame not recorded | Nereus Pharmaceuticals, Inc. | Private Life Biomed AG | Security Agreement |
| May 21, 2009 reel/frame not recorded | Nereus Pharmaceuticals, Inc. | Alstertor Private Life GmbH & Co. KG | Security Agreement |
| May 21, 2009 reel/frame not recorded | Nereus Pharmaceuticals, Inc. | Advent Healthcare and Life Sciences III Limited Partnership | Security Agreement |
| May 21, 2009 reel/frame not recorded | Nereus Pharmaceuticals, Inc. | Advent Healthcare and Life Sciences III-A Limited Partnership | Security Agreement |
| May 21, 2009 reel/frame not recorded | Nereus Pharmaceuticals, Inc. | Advent Partners HLS III Limited Partnership | Security Agreement |
| May 21, 2009 reel/frame not recorded | Nereus Pharmaceuticals, Inc. | Pacific Venture Group II, L.P. | Security Agreement |
| May 21, 2009 reel/frame not recorded | Nereus Pharmaceuticals, Inc. | Pvg Associates Ii, L.p. | Security Agreement |
| May 21, 2009 reel/frame not recorded | Nereus Pharmaceuticals, Inc. | Forward Ventures Iv, L.p. | Security Agreement |
| May 21, 2009 reel/frame not recorded | Nereus Pharmaceuticals, Inc. | Forward Ventures IV B, L.P. | Security Agreement |
| May 21, 2009 reel/frame not recorded | Nereus Pharmaceuticals, Inc. | Gimv N.V. | Security Agreement |
| May 21, 2009 reel/frame not recorded | Nereus Pharmaceuticals, Inc. | Gimv Adviesbeheer Life Sciences N.V. | Security Agreement |
| May 21, 2009 reel/frame not recorded | Nereus Pharmaceuticals, Inc. | Lotus Bioscience Investment Holds Ltd. | Security Agreement |
| May 21, 2009 reel/frame not recorded | Nereus Pharmaceuticals, Inc. | Novartis Bioventure Fund / Novartis International Aig | Security Agreement |
| May 21, 2009 reel/frame not recorded | Nereus Pharmaceuticals, Inc. | Hensler, Mary | Security Agreement |
| May 21, 2009 reel/frame not recorded | Nereus Pharmaceuticals, Inc. | Jacobs, Robert | Security Agreement |
| May 21, 2009 reel/frame not recorded | Nereus Pharmaceuticals, Inc. | WS Investment Company | Security Agreement |
| May 21, 2009 reel/frame not recorded | Nereus Pharmaceuticals, Inc. | Genavent Partners LP | Security Agreement |
| May 21, 2009 reel/frame not recorded | Nereus Pharmaceuticals, Inc. | Astellas Venture Fund I LP | Security Agreement |
| May 21, 2009 reel/frame not recorded | Nereus Pharmaceuticals, Inc. | Roche Finance Ltd. | Security Agreement |
| May 21, 2009 reel/frame not recorded | Nereus Pharmaceuticals, Inc. | Alta California Partners II, L.P. | Security Agreement |
| May 21, 2009 reel/frame not recorded | Nereus Pharmaceuticals, Inc. | Alta Embarcadero Partners II, LLC | Security Agreement |
| May 21, 2009 reel/frame not recorded | Nereus Pharmaceuticals, Inc. | Alta California Partners II, L.P. - New Pool | Security Agreement |
| Feb 28, 2013 Reel 29899, frame 101 | Nereus Pharmaceuticals, Inc. | Triphase Research and Development I Corp. | Assignment of Assignor's Interest |
| Nov 15, 2016 Reel 40327, frame 264 | HBM Vioventures (Cayman) Ltd.; HBM Biocapital (Eur) L.P.; HBM Biocapital (Usd) L.P.; Private Life Biomed AG; Alstertor Private Life GmbH & Co. KG; Advent Healthcare and Life Sciences III Limited Partnership; Advent Healthcare and Life Sciences III-A Limited Partnership; Advent Partners HLS III Limited Partnership; Pacific Venture Group II, L.P.; Pvg Associates Ii, L.p.; Forward Ventures Iv, L.p.; Forward Ventures IV B, L.P.; Gimv N.V.; Gimv Adviesbeheer Life Sciences N.V.; Lotus Bioscience Investment Holds Ltd.; Novartis Bioventure Fund / Novartis International Aig; Hensler, Mary; Jacobs, Robert; WS Investment Company; Genavent Partners LP; Astellas Venture Fund I LP; Roche Finance Ltd.; Alta California Partners II, L.P.; Alta Embarcardero Partner II, LLC; Alta California Partners II, L.P. - New Pool | Nereus Pharmaceuticals, Inc. | Release of Security Interest |
| Feb 13, 2017 Reel 41698, frame 404 | Nereus Pharmaceuticals, Inc. | Triphase Research and Development I Corp. | Assignment of Assignor's Interest |
| Apr 29, 2024 Reel 67256, frame 264 | Celgene Research and Development I ULC, Formerly Known as Triphase Research and Development I Corp. | 1096271 B.C. Unlimited Liability Company | Assignment of Assignor's Interest |
| Apr 29, 2024 Reel 67256, frame 286 | 1096271 B.C. Unlimited Liability Company | Celgene Tri a Holdings Ltd. | Assignment of Assignor's Interest |
| Apr 29, 2024 Reel 67256, frame 305 | Celgene Tri a Holdings Ltd. | Celgene International II SARL | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Jun 2033
Term ends Jun 23, 2033.
Note
The 2099 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
3
later US patents cite this one
That is below the median of utility patents granted in 2015 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.